NVIDIA spotlights three Inception program startups using AI to address gaps in breast cancer care, from screening through treatment planning. The article notes that many women skip annual screening, radiologist capacity is shrinking, and genomic assays can take weeks to return results.
iSono Health's FDA-cleared ATUSA system is a wearable automated ultrasound that captures standardized 3D breast volumes in about two minutes, compared with up to 45 minutes for a handheld exam. The company says its AI, trained on over 1.5 million ultrasound frames, makes the scan 28% more sensitive than handheld 2D ultrasound and enables repeatable comparisons across visits. Whiterabbit.ai's FDA-cleared WRDensity software assesses breast density, and its WRRisk estimates long-term cancer risk; the company is also researching AI that could help radiologists detect cancers while automating negative screening reads. Ataraxis AI analyzes digital pathology slides and clinical variables to predict treatment response and recurrence risk, potentially reducing the need for separate tissue biopsies and long waits.
Because only one source was provided, there is no independent perspective to compare against. The claims are presented as reported by NVIDIA and reflect the company's view of its ecosystem's AI infrastructure.